Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR, Brue T, Schilbach K, Ignatenko S, Magony S, Chung YS, Kim BJ, Hur KY, Kang HC, Kim JH, Kim MS, Kowalska A, Bolanowski M, Ruchala M, Damjanovic S, Payer J, Choi YJ, Heo SJ, Kim TK, Heo M, Lee J, Lee EJ.
Ku CR, et al. Among authors: kim ms, kim tk, kim bj, kim jh.
Eur J Endocrinol. 2018 Sep;179(3):169-179. doi: 10.1530/EJE-18-0185. Epub 2018 Jul 4.
Eur J Endocrinol. 2018.
PMID: 29973375
Clinical Trial.